Bone metabolism and mineral density in patients with beta-thalassemia major

Saudi Medical Journal

Volumn 28, Issue 9, 2007, Pages 1425-1429

  Dundar, Umit ^a   Kupesiz, Alphan ^b   Ozdem, Sebahat ^b   Gilgil, Erdal ^b   Tuncer, Tiraje ^b   Yesilipek, Akif ^b   Gultekin, Meral ^b  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCITONIN; DEFEROXAMINE; ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; OSTEOCALCIN; PHOSPHORUS; PROGESTERONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCITONIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUMBAR SPINE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; THALASSEMIA MAJOR; TURKEY (REPUBLIC); BETA THALASSEMIA; BONE REMODELING; CASE CONTROL STUDY; METABOLISM; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BONE DENSITY; BONE REMODELING; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 38849184792     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-915.
2. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J, et al. Abnormal bone metabolism in thalassaemia. In: Ando S, Brancati C, editors. Endocrine Disorders in Thalassemia. Berlin: Springer; 1995. p. 39-46.
3. Soliman AT, El Banna N, Abdel Fattah M, ElZalabani MM, Ansari BM. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998; 47: 541-548.
4. Lasco A, Morabito N, Guadio A, Crisafulli A, Meo A, Denuzzo G, et al. Osteoporosis and beta-thalassemia major: Role of the IGF-1/IGFBP-III axis. J Endocrinol Invest 2002; 25: 338-344.
5. el-Hazmi MA, Warsy AS, al-Fawaz I. Iron-endocrine pattern in patients with beta-thalassaemia. J Trop Pediatr 1994; 40: 219-224.
6. Clegg JB, Weatherall DJ. The thalassemia syndrome. 3rd ed. Oxford (UK): Blackwell scientific; 1985. p. 157-190.
7. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112: 36-41.
8. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I. Bone mineral density of patients with thalassemia major: four year follow-up. Calcif Tissue Int 1999; 64: 481-484.
9. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int 2002; 13: 644-649.
10. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High incidence of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 975-977.
11. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A. Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 785-790.
12. Lasco A, Morabito A, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporosis Int 2001; 12: 570-575.
13. Bielinski BK, Darbyshire P, Mathers L, Boivin CM, Shaw NJ. Bone density in the asian thalassaemic population: A cross-sectional review. Acta Paediatr 2001; 90: 1262-1266.
14. Anapliotou MLG, Kastanias IT, Psara P Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: New therapeutic approaches. Clin Endoc 1995; 42: 279-287.
15. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Bone Miner Res 1999; 14: 1583-1595.
16. Brook CG, Hindmarsh PC. The somatotropic axis in puberty. Endocrinol Metab Clin North Am 1992; 21: 767-782.
17. Aynsley-Green A, Zachmann M, Prader A. Interrelation of the therapeutic effect of growth hormone and testosterone on growth in hypopituitarism. J Pediatr 1976; 89: 992-999.
18. Tanner JM, Whitehouse RH, Hughes PC Carter BS. Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length, limb length and muscle width in growth hormone deficient children. J Pediatr 1976; 89: 1000-1008.
19. Harris DA, Van Vliet G, Egli CA, Grumbach MM, Kaplan SL, Styne DM, et al. Somatomedin C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 1985; 61: 152-159.
20. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop Relat Res 1991; 263: 30-48.
21. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. Short term effects of recombinant human insulin like growth factor-I on bone turnover in normal women. J Clin Endocrinol Metab 1993; 77: 1384-1387.
22. Delany AM, Pash JM, Canalis E. Cellular and clinical perspectives on skeletal insulin like growth factors I. J Cell Biochem 1994; 55: 328-333.
23. Tanaka H, Quarto R, Williams S, Barnes J, Liang CT. In vivo and in vitro effects of insulin like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone 1994; 15: 647-653.
24. Narusawa K, Nakamura T, Suzuki K, Matsuoka Y, Lee LJ, Tanaka H, et al. The effects of recombinant human insulin like growth factor (rhIGF)-I and rhIGF-I/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res 1995; 10: 1853-1864.
25. Flynn DM, Fairney A Jackson D Clayton BE. Hormonal changes in thalassemia major. Arch Dis Child 1976; 51: 828-836.
26. Alagna S, Masala A, Gallisai D, Ginanni A, Burrai C, Pinna A et al. Parathyroid function and bone metabolism in children with beta thalassaemia major: Effects of sex steroid treatment. Eur J Med 1992; 1: 153-157.
27. Friedman J, Au WY, Raisz LG. Responses of fetal rat bone to thyrocalcitonin in tissue culture. Endocrinology 1968; 82: 149-156.
28. Canatan D, Akar N, Arcasoy A. Effect of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995; 93: 20-24.
29. Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. Osteoporos Int 1998; 8: 423-427.